161 The impact of class III obesity on maternal and neonatal outcomes in preeclamptic patients 
OBJECTIVE:
The rate of obesity is increasing in women of reproductive age, and obesity is a major risk factor for preeclampsia. Our objective was to compare maternal and neonatal morbidity and mortality in preeclamptic patients between those with a BMI <40 and a BMI ! 40 (class III obesity). STUDY DESIGN: We conducted a secondary analysis of a multicenter prospective cohort study (PE Triage by Rapid Assay-PETRA trial). The study's primary objective was to validate placental growth factor as a biomarker for preeclampsia. Pregnant women at 20 0/7 to 40 0/7 weeks gestation who presented with signs or symptoms of preeclampsia (PE) were enrolled at 24 centers in the United States and Canada. The diagnosis of preeclampsia and other pregnancy complications were subsequently formulized by an adjudication group using standardized diagnostic criteria. Primary outcome was a composite neonatal morbidity (CNM) comprised of IVH (grade 3-4), NEC, BPD and perinatal death. Secondary outcomes were the components of CNM; small for gestational age (SGA) and gestational age at delivery (GA at del.) as well as maternal morbidity: abruption, renal failure, pulmonary edema, HELLP and eclampsia. hypertension and pre-gestational diabetes which were higher in those with a BMI ! 40 (Table 1 ). There were no significant differences in CNM between the 2 groups, however the BMI <40 subgroup had a higher rate of delivery at early and late preterm gestations (Table 2) . Maternal morbidity was rare in both groups. CONCLUSION: In preeclamptic patients, maternal and neonatal morbidity is not increased in women with class III obesity. However, patients with class III obesity developed preeclampsia at a later gestational age.
162 How often do physicians follow national guidelines for the diagnosis of hypertensive diseases of pregnancy? 
The formulation of an accurate diagnosis influences delivery timing, and thus impacts pregnancy outcomes.It remains unclear how often physicians in clinical practice follow our national organization's diagnostic criteria recommendations for hypertensive diseases of pregnancy (HDP). Our aim was to compare HDP diagnoses made by clinicians to those generated by experts who reviewed charts and adjudicated diagnoses.Further, we reviewed the clinical implications of the diagnoses made on timing of delivery. STUDY DESIGN: We conducted a secondary analysis of a multicenter prospective cohort study designed to evaluate serum PlGF in predicting adverse pregnancy outcome in women who presented with signs or symptoms of preeclampsia (PE). The study was performed in 24 centers in the US and Canada. The diagnosis and management criteria used were prior to the Hypertension in Pregnancy Task Force Guidelines publication. We reviewed patients who received the final diagnosis of preeclampsia (mild or severe), atypical preeclampsia, chronic hypertension, gestational hypertension (mild or severe), HELLP, eclampsia and those who remained non hypertensive.We then compared the diagnosis made by managing physicians to that adjudicated by experts who reviewed the charts. We also valuated the impact of asynchronous diagnosis on gestational age at delivery recommendations. RESULTS: 869 patients were included,of which 404 (46%) had a discordant diagnosis between investigator and adjudicators (figure 1). These differences in diagnoses would have affected delivery recommendations for 314 patients. All 31 patients undergoing immediate delivery per the investigator diagnosis, received diagnoses by the adjudicators that did not warrant immediate delivery (figure 2). On the other hand, all 25 patients that had a diagnosis consistent with expectant management by the investigators, would have been delivered earlier based on adjudicated diagnosis. Furthermore 65% of patients with a clinician diagnosis that recommended delivery at 37-39 weeks would have been delivered earlier by the expert adjudicator.
CONCLUSION:
The implications of lack of compliance with guideline recommendations for diagnosis and management of HDP amongst clinicians are concerning since they could lead to adverse pregnancy outcome. Future studies are needed to investigate the reasons for non-adherence with guideline recommendations in clinical practice.
163 Quantification of blood loss during cesarean delivery using an iPad based application (Triton) OBJECTIVE: To compare measurement of blood loss using the quantitative Triton system (Gauss Surgical, Inc., Los Altos, CA) with other measures of blood loss in women who underwent cesarean delivery. STUDY DESIGN: We included all women scheduled for cesarean delivery at our facility. Intraoperative blood loss was measured using the Triton, which was masked to the clinical team, as well as estimated by the surgeon (EBL). The relation between the two methods (Triton and EBL) and post-op Hgb as well as DHgb (post-op minus pre-op Hgb) was determined using bivariate and multivariate linear regressions. Triton measurement and EBL were compared between women with DHgb in the upper quartile (cases) versus all other quartiles (control). Prediction of DHgb in the upper quartile was also evaluated for each method, and the area under the ROC curves (AUCs) was compared. McNemar and Mann-Whitney tests were used. RESULTS: The trial enrolled 109 patients. The mean blood loss estimated by Triton was significantly lower than that estimated by EBL (437.5 AE 267.8 vs. 839.9 AE 244.7 mL, P<.0001). By bivariate analysis, DHgb correlated with Triton estimate but not EBL (Figure) . 30 patients had DHgb in the upper quartile (DHgb ! 2 g/dL). There was significant difference in the Triton blood loss measurement between cases and controls, but no difference in EBL (Table) . Triton, but not EBL, was predictive of DHgb ! 2 g/dL (Triton ROC AUC:
